More importantly, we found that CPVL promoted drug resistance to CDK4/6 inhibitors by downregulating phosphatase and tensin homolog (PTEN) in vivo and in vitro, indicating that CPVL promotes breast cancer resistance to CDK4/6 inhibitors. This evidence concerns the gene CPVL and breast carcinoma.